{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T03:38:58Z","timestamp":1789875538233,"version":"4.0.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2014,3,15]],"date-time":"2014-03-15T00:00:00Z","timestamp":1394841600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1007\/s40264-014-0149-8","type":"journal-article","created":{"date-parts":[[2014,3,18]],"date-time":"2014-03-18T05:56:40Z","timestamp":1395122200000},"page":"269-282","source":"Crossref","is-referenced-by-count":19,"title":["Thromboembolic Events in Women Exposed to Hormonal Contraception or Cyproterone Acetate in 2012: A Cross-Sectional Observational Study in 30 French Public Hospitals"],"prefix":"10.1007","volume":"37","author":[{"name":"The French Network of Regional Pharmacovigilance Centres","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde","family":"Gourbil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Grandvuillemin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-No\u00eblle","family":"Beyens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Massy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Gras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9a","family":"D\u2019Amico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghada","family":"Miremont-Salam\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Petitpain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,3,15]]},"reference":[{"key":"149_CR1","doi-asserted-by":"crossref","unstructured":"World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: results of international multicenter case-control study. Lancet. 1995;346:1575\u201382.","DOI":"10.1016\/S0140-6736(95)91926-0"},{"key":"149_CR2","unstructured":"ANSM. Quelle est la situation actuelle des pilules oestroprogestatives en France? http:\/\/ansm.sante.fr\/Dossiers\/Pilules-estroprogestatives-et-risque-thrombotique\/ ."},{"key":"149_CR3","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0010-7824(01)00307-9","volume":"65","author":"\u00d8 Lidegaard","year":"2002","unstructured":"Lidegaard \u00d8, Edstrom B, Kreiner B. Oral contraceptives and venous thromboembolism: a five-year national case-control study. Contraception. 2002;65:187\u201396.","journal-title":"Contraception"},{"key":"149_CR4","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.contraception.2006.02.002","volume":"73","author":"SS Jick","year":"2006","unstructured":"Jick SS, Kaye JA, Russmann S, et al. Risk of nonfatal venous thromboembolism with oral contraceptives containing norgestimate or desogestrel compared with oral contraceptives containing levonorgestrel. Contraception. 2006;73:566\u201370.","journal-title":"Contraception"},{"key":"149_CR5","doi-asserted-by":"crossref","unstructured":"van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, Doggen CJ, Rosendaal FR. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ. 2009;339:b2921.","DOI":"10.1136\/bmj.b2921"},{"key":"149_CR6","doi-asserted-by":"crossref","first-page":"b2890","DOI":"10.1136\/bmj.b2890","volume":"339","author":"\u00d8 Lidegaard","year":"2009","unstructured":"Lidegaard \u00d8, L\u00f8kkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ. 2009;339:b2890.","journal-title":"BMJ"},{"key":"149_CR7","doi-asserted-by":"crossref","first-page":"d6423","DOI":"10.1136\/bmj.d6423","volume":"343","author":"\u00d8 Lidegaard","year":"2011","unstructured":"Lidegaard \u00d8, Nielsen LH, Skovlund CW, Skjeldestad FE, L\u00f8kkegaard E. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9. BMJ. 2011;343:d6423.","journal-title":"BMJ"},{"key":"149_CR8","doi-asserted-by":"crossref","first-page":"d2151","DOI":"10.1136\/bmj.d2151","volume":"342","author":"SS Jick","year":"2011","unstructured":"Jick SS, Hernandez RK. Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data. BMJ. 2011;342:d2151.","journal-title":"BMJ"},{"key":"149_CR9","doi-asserted-by":"crossref","first-page":"d2139","DOI":"10.1136\/bmj.d2139","volume":"342","author":"L Parkin","year":"2011","unstructured":"Parkin L, Sharples K, Hernandez RK, Jick SS. Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database. BMJ. 2011;342:d2139.","journal-title":"BMJ"},{"key":"149_CR10","doi-asserted-by":"crossref","first-page":"E1319","DOI":"10.1503\/cmaj.110463","volume":"183","author":"N Gronich","year":"2011","unstructured":"Gronich N, Lavi I, Rennert G. Higher risk of venous thrombosis associated with drospirenone-containing oral contraceptives: a population-based cohort study. CMAJ. 2011;183:E1319\u201325.","journal-title":"CMAJ"},{"key":"149_CR11","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.beem.2012.11.002","volume":"27","author":"G Plu-Bureau","year":"2013","unstructured":"Plu-Bureau G, Maitrot-Mantelet L, Hugon-Rodin J, Canonico M. Hormonal contraceptives and venous thromboembolism: an epidemiological update. Best Pract Res Clin Endocrinol Metab. 2013;27:25\u201334.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"149_CR12","unstructured":"FDA. Combined hormonal contraceptives (CHCs) and the risk of cardiovascular disease endpoints, final report 111022v2. http:\/\/www.fda.gov\/downloads\/Drugs\/DrugSafety\/UCM277384.pdf . Accessed 4 Oct 2013."},{"key":"149_CR13","unstructured":"European Medicines Agency. Safety monitoring of medicines. Combined hormonal contraceptives. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Referrals_document\/Combined_hormonal_contraceptives\/Recommendation_provided_by_Pharmacovigilance_Risk_Assessment_Committee\/WC500151959.pdf . Accessed 30 Oct 2013."},{"key":"149_CR14","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1056\/NEJMoa1111840","volume":"366","author":"\u00d8 Lidegaard","year":"2012","unstructured":"Lidegaard \u00d8, L\u00f8kkegaard E, Jensen A, Skovlund CW, Keiding N. Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med. 2012;366:2257\u201366.","journal-title":"N Engl J Med"},{"key":"149_CR15","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.beem.2012.11.003","volume":"27","author":"G Plu-Bureau","year":"2013","unstructured":"Plu-Bureau G, Hugon-Rodin J, Maitrot-Mantelet L, Canonico M. Hormonal contraceptives and arterial disease: an epidemiological update. Best Pract Res Clin Endocrinol Metab. 2013;27:35\u201345.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"149_CR16","doi-asserted-by":"crossref","unstructured":"Stegeman BH, de Bastos M, Rosendaal FR, van Hylckama Vlieg A, Helmerhorst FM, Stijnen T, et al. Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network meta-analysis. BMJ. 2013;347:f5298.","DOI":"10.1136\/bmj.f5298"},{"key":"149_CR17","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.ando.2012.09.001","volume":"73","author":"P Gourdy","year":"2012","unstructured":"Gourdy P, Bachelot A, Catteau-Jonard S, Chabbert-Buffet N, Christin-Ma\u00eetre S, Conard J, et al. Hormonal contraception in women at risk of vascular and metabolic disorders: guidelines of the French Society of Endocrinology. Ann Endocrinol (Paris). 2012;73:469\u201387.","journal-title":"Ann Endocrinol (Paris)"},{"key":"149_CR18","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1161\/CIRCULATIONAHA.109.921460","volume":"121","author":"AG Holst","year":"2010","unstructured":"Holst AG, Jensen G, Prescott E. Risk factors for venous thromboembolism: results from the Copenhagen city heart study. Circulation. 2010;121:1896\u2013903.","journal-title":"Circulation"},{"key":"149_CR19","unstructured":"Beck F, Guignard R, Richard JB, Wilquin JL, Peretti-Watel P. Increasing trends in smoking in France: main results of the French Health Barometer, France 2010. BEH. Special issue\u2014World No Tobacco Day, 2011;20\u201321:230\u201333."},{"key":"149_CR20","unstructured":"Department of Reproductive Health and Research, World Health Organization. Medical eligibility criteria for contraceptive use. 4th ed. 2009. A WHO family planning cornerstone. Geneva: World Health Organization, 2010. http:\/\/whqlibdoc.who.int\/publications\/2010\/9789241563888_eng.pdf . Accessed 4 Oct 2013."},{"key":"149_CR21","unstructured":"Centers for Disease Control. US. Medical Eligibility Criteria for Contraceptive Use, 2010: adapted from the World Health Organization Medical Eligibility Criteria for Contraceptive Use, 4th ed. MMWR Recomm Rep 2010 June 18;59 (RR-4), p. 1\u201386."},{"key":"149_CR22","unstructured":"Cnamts-DSES-DESP. [Combined oral contraceptives and risk of pulmonary embolism, stroke and myocardial infarction: a cohort study of 4 million French women]. http:\/\/ansm.sante.fr\/Dossiers-thematiques\/Pilules-estroprogestatives-et-risque-thrombotique\/Quelles-sont-les-donnees-sur-le-risque-thromboembolique-veineux-issues-des-etudes-de-pharmacoepidemiologie\/(offset)\/5 . Accessed 4 Oct 2013."},{"key":"149_CR23","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","volume":"29","author":"L Hazell","year":"2006","unstructured":"Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006;29:385\u201396.","journal-title":"Drug Saf"},{"key":"149_CR24","unstructured":"ANSM. Quelle est la situation actuelle des pilules estroprogestatives en France? http:\/\/ansm.sante.fr\/Dossiers-thematiques\/Pilules-estroprogestatives-et-risque-thrombotique\/Quelle-est-la-situation-actuelle-des-pilules-estroprogestatives-en-France\/(offset)\/1 . Accessed 4 Oct 2013."},{"key":"149_CR25","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1182\/blood-2008-01-077909","volume":"112","author":"B Dahlb\u00e4ck","year":"2008","unstructured":"Dahlb\u00e4ck B. Advances in understanding pathogenic mechanisms of thrombophilic disorders. Blood. 2008;112:19\u201327.","journal-title":"Blood"},{"key":"149_CR26","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1046\/j.1365-2141.2001.02813.x","volume":"113","author":"AC Dykes","year":"2001","unstructured":"Dykes AC, Walker ID, McMahon AD, Islam SI, Tait RC. A study of Protein S antigen levels in 3788 healthy volunteers: influence of age, sex and hormone use, and estimate for prevalence of deficiency state. Br J Haematol. 2001;113:636\u201341.","journal-title":"Br J Haematol"},{"key":"149_CR27","unstructured":"HAS. Strat\u00e9gies de choix des m\u00e9thodes contraceptives chez la femme. Recommandations pour la pratique clinique. Service des recommandations professionnelles de l\u2019Anaes. D\u00e9cembre 2004. http:\/\/www.choisirsacontraception.fr\/pdf\/contraception_recommandations_has.pdf . Accessed 4 Oct 2013."},{"key":"149_CR28","unstructured":"Contraceptifs oraux combin\u00e9s et risque de thrombose veineuse : prescription des pilules de 2e g\u00e9n\u00e9ration contenant du l\u00e9vonorgestrel en premi\u00e8re intention\u2014Point d\u2019information. Octobre 2012. http:\/\/ansm.sante.fr\/content\/download\/43790\/568981\/version\/2\/file\/pi-121001-COC.pdf ."},{"key":"149_CR29","unstructured":"Benefits of combined hormonal contraceptives (CHCs) continue to outweigh risks\u2014CHMP endorses PRAC recommendation. November 2013. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Press_release\/2013\/11\/WC500155455.pdf ."}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-014-0149-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40264-014-0149-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-014-0149-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T19:41:32Z","timestamp":1559504492000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40264-014-0149-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,15]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["149"],"URL":"https:\/\/doi.org\/10.1007\/s40264-014-0149-8","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,15]]}}}